Pulmonary Arterial Hypertension, Pulmonary Hypertension, Pulmonary Hypertension Chronic Thromboembolic
Conditions
Keywords
pulmonary hypertension, medication reconciliation, medication errors, pharmacist, rare disease
Brief summary
Pulmonary hypertension (PH) is a life threatening condition. In PH, pulmonary arterial hypertension (PAH) and chronic thrombo-embolic chronic pulmonary hypertension (CTEPH) are two rare diseases requiring specific and complex drug management. In France ,a part of these treatments ,only available in hospital pharmacies, are generally unknown from community health care professionals despite the high risk of drug-interactions and side effects. Anticipating medication errors at the begging of the disease is therefore important, and could be done through medication reconciliation.
Detailed description
Medication reconciliation (MR) will be done for patients hospitalized in the French referral center for PH for PAH or CTEPH. Detected medication errors will be tracked and fixed by the physician before the end of hospitalization. A synthesis of new/stopped and modified treatments will be given to the patient as well as his related healthcare professionals (community pharmacist and general practioner) to ensure the maintaining of the new therapeutic management and the understanding of drugs modification. To compare the potential decrease of medication errors promoted by MR, a retrospective MR will be also done for patients without MR at 1st hospitalization but at the next one (3 to 12 months after).
Interventions
OTHERMedication reconciliation
MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.
Sponsors
Agence Regionale de Sante d'Ile de France
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient affiliated or entitled to a social security scheme * At least 18 years old * Patient with enlightened information of the study and not opposed with it. * For patient without MR: patient hospitalized for the first re-evaluation of PAH or CTEPH within 12 months following the first assessment hospitalization (ie: first right heart catheterization at bicetre Hospital). * For patient with MR: patient hospitalized for first assessment (first right heart catheterization at bicetre Hospital) of PAH or CTEPH
Exclusion criteria
* Patient suffering from another form of PH * Patient under guardianship or curator * Inability to give information to the patient either due to language barrier or to cognitive impairment * Patient hosted in institution on discharge from hospital (follow-up care and long-term rehabilitation) * Patient with a life expectancy of less than 1 year * Patient on transplant list * Patient refusal * Length of stay \< 48 hours
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients having at least one medication error on discharge at the first hospitalization. | 12months | This group will be compared to patients without prospective MR. For the latter group, MR is retrospective (3 to 6 months after discharge). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Medication errors status | 12 Months | corrected/not corrected |
| Identification of medication error severity | 12 months | Cornish scale is the title of the scale which include 3 levels of gravity (from 1 to 3). The first one describes no relevant clinical impact and the third one describes a severe clinical impact. |
| Satisfaction of community healthcare practitioners with study tools | 12 months | healthcare practitioners will be contacted by mail or phone |
| Therapeutic adherence | within 12 months after first hospitalization for the diagnosis of the disease | Observance Girerd auto-questionnaire |
| Qualitative description of identified medication errors. | 12 months | Omission, dosing errors, drug interactions, substitution of another active compound |
| Improve vaccination coverage against influenza and pneumococcal disease | within 12 months after first hospitalization for the diagnosis of the disease | inclusion vaccination coverage rate vs EOS(Enhanced Outreach Strategy) vaccination coverage rate |
| Emergency hospitalization | within 12 months after first hospitalization for the diagnosis of the disease | Number of emergency hospitalizations between first assessment hospitalization (diagnosis) and first reassessment hospitalization |
| Estimate the time and resources spent on the conciliation process in the department | 12 months | Time measurement of the conciliation process in the group with CM (in minutes) |
| Measure of Quality of life | within 12 months after first hospitalization for the diagnosis of the disease | Short Form 36 Questionnaire |
Countries
France
Outcome results
None listed